(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland - 2How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- 3Manual for 6 Hot Brilliant Beds
- 4Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- 54 Must-Visit bar-b-que Eateries This Year
- Home Plan Tips for Seniors
- Which Switch Game Do You Suggest? Share Your Decision
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Cyprus: War-related tourism concerns and climate change efforts
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
- 5 Must-Attempt Fascinating Dishes from Around the World
- European nations criticise Israel’s death penalty plans
- Dinosaur collagen used to create one-of-a-kind handbag
